title: [Expression of thioredoxin-2 for monitoring minimal residual disease in acute leukemia].
abstract: OBJECTIVE
  To investigate the significance of human thioredoxin-2 (TRX-2) in monitoring minimal residual disease (MRD) in acute leukemia (AL).
  
  
  METHODS
  We used real-time quantitative PCR to serially quantitize TRX-2 expression levels in the bone marrow of AL patients at diagnosis (n=68), at complete hematologic remission (CHR, n=57) and at relapse (n=25). Another 25 normal donors served as normal controls. The upper limit of the bone marrow at 91 was regarded as the reference. TRX-2 expression level at CHR with <5% blast cells in the bone marrow of relapse patients was analyzed and compared with MRD by flow cytometry.
  
  
  RESULTS
  The TRX-2 levels between the CHR patients and newly diagnosed patients, and between the CHR patients and the relapse patients had significant difference. TRX-2 expression level of 21(21/25) relapse patients at CHR with <5% blast cells in the bone marrow was higher than the reference (>91). TRX-2 level was correlated to the expression level of MRD.
  
  
  CONCLUSIONS
  TRX-2 may be the marker for AL and used in MRD monitoring.
authors: Department of Hematology, Guangdong Academy of Medical Sciences, Guangzhou, China.
authors: Qiong
authors: Q
authors: Luo
authors: Zhixin
authors: Z
authors: Huang
authors: Liuping
authors: L
authors: Luo
authors: Dingzhang
authors: D
authors: Xiao
mesh_terms: D016022:Case-Control Studies; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism*; D008297:Male; D018365:Neoplasm, Residual / Q000175:diagnosis*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism*; D060888:Real-Time Polymerase Chain Reaction; D013879:Thioredoxins / Q000235:genetics / Q000378:metabolism*
chemical_list: D013879:Thioredoxins